Synergistic combination of doxorubicin with hydralazine, and disulfiram against MCF-7 breast cancer cell line

Disulfiram and hydralazine have recently been reported to have anti-cancer action, and repositioned to be used as adjuvant in cancer therapy. Chemotherapy combined with other medications, such as those that affect the immune system or epigenetic cell profile, can overcome resistance with fewer adver...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2023-09, Vol.18 (9), p.e0291981-e0291981
Hauptverfasser:	Lafi, Zainab, Alshaer, Walhan, Gharaibeh, Lobna, Alqudah, Dana A, AlQuaissi, Baidaa, Bashaireh, Banan, Ibrahim, Abed Alqader
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvant treatment Analysis Apoptosis Biology and Life Sciences Breast cancer Cancer Cancer therapies Care and treatment Cell viability Chemotherapy Complications and side effects Cytotoxicity Dehydrogenases Diagnosis Disulfiram DNA methylation Doxorubicin Drug resistance Drug therapy, Combination Enzymes Epigenetic inheritance Epigenetics Flow cytometry Gene expression Health aspects Hydralazine Hydrazine Hydrazines Immune system Immunosuppressive agents Medical prognosis Medicine and Health Sciences Metastasis Patient outcomes Software Stem cells Synergism Vorinostat
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!